SNS-032

TargetMol
Product Code: TAR-T6049
Supplier: TargetMol
CodeSizePrice
TAR-T6049-5mg5mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6049-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6049-10mg10mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6049-25mg25mg£141.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6049-50mg50mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6049-100mg100mg£251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6049-200mg200mg£338.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6049-500mg500mg£519.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
SNS-032 is a selective inhibitor of CDK2 (IC50: 48 nM ) and is 10- and 20-fold selective over CDK1/CDK4. It is also sensitive to CDK7/9 (IC50: 62 nM/4 nM), and no effect on CDK6.
CAS:
345627-80-7
Formula:
C17H24N4O2S2
Molecular Weight:
380.53
Pathway:
Cell Cycle/Checkpoint; PI3K/Akt/mTOR signaling; Apoptosis; Stem Cells
Purity:
0.9944
SMILES:
CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1
Target:
Apoptosis; GSK-3; CDK

References

Guo S, Lei X, Chang Y, et al.SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis.Signal Transduction and Targeted Therapy.2022, 7(1): 1-12. Chen R, et al. Blood, 2009, 113(19): 4637-45. Conroy A, et al. Cancer Chemother Pharmacol, 2009, 64(4), 723-32. Walsby E, et al. Leukemia, 2011, 25(3), 411-9. Ali MA, et al. Neoplasia, 2007, 9(5), 370-81. Zhang G M, Huang S S, Ye L X, et al. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Pharmacological Research. 2022: 106464.